timothy sykes logo
10x Genomics Stock Jumps As Atera Rollout Fuels Bullish Targets Thumbnail
G Google News

10x Genomics Stock Jumps As Atera Rollout Fuels Bullish Targets

ELLIS HOBBS•UPDATED OCT. 2, 2026, 4:08 PM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

10x Genomics Inc. stocks have been trading up by 5.34 percent after upbeat coverage on its expanding single-cell sequencing demand.

What Traders Need To Know

  • Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, far above the Street’s ~$58.80 average and an already Overweight stance.
  • Strong early demand for the new Atera spatial biology platform, already running above current manufacturing capacity, is central to the bullish case and its AI-driven drug discovery angle.
  • Piper Sandler lifted its TXG price target from $47 to $80 (Neutral), while Leerink boosted from $40 to $90 (Market Perform), signaling a broad upward reset in expectations.
  • Recent rallies included a 7.6% intraday jump to $81.33 and an additional ~3% gain around the Argus initiation, showing traders are reacting aggressively to the new narrative.
  • Commercial shipments of Atera have started, moving TXG from launch story to real customer deployment across research and biopharma accounts.

Candlestick Chart

Weekly Update Sep 28 – Oct 02, 2026: On Friday, October 02, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 5.34%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

10x Genomics occupies a leadership position in single-cell and spatial biology, supported by 70% gross margins and mid‑single‑digit revenue CAGR over three years, accelerating on a five‑year basis. However, operating metrics remain loss‑making, with EBIT margin at roughly –13% and ROIC consistently negative, reflecting heavy R&D and commercial spend. The balance sheet is a clear strength: current ratio 5.7, minimal leverage (total debt/equity 0.1), and over $500 million in cash, providing multi‑year runway despite negative GAAP earnings.

Technically, TXG is in a strong short‑term uptrend, with the stock moving from the low‑80s to the low‑90s and printing successive higher highs into $93.50. Intraday 5‑minute action shows persistent dip‑buying and rising volume on up‑moves, confirming institutional participation. The key actionable level is $88–89, now a pivotal support zone; as long as price holds above this band on closing and volume remains elevated, pullbacks are attractive buys with a trading target near recent high resistance around $95.

Fundamentally and relative to Healthcare and Biotechnology & Life Sciences peers, TXG trades at a premium (P/S ~19x, P/B ~14x) but justifies it with category‑defining technology and strong product momentum. The Atera launch, above‑capacity demand, and analyst target resets (Deutsche $70, Piper $80, Leerink $90, Argus $110) materially de‑risk the growth narrative. I expect continued multiple support and upside toward $100 over 12 months, with technical resistance at $95 and support anchored at $88.

More Breaking News

Quick Financial Overview

10x Genomics Inc. sits at an interesting crossroads for traders. The stock has pushed into the low $90s, with recent weekly closes climbing from the low $80s to around $93.50. That move has come as Wall Street re-rates TXG sharply higher, with targets now clustered between $70 and $110. For short-term traders, this is classic “news plus repricing” action, where expectations reset before fundamentals fully catch up.

Under the hood, TXG is still a high-growth, loss-making name. Trailing revenue is about $642.8M, with a strong 70% gross margin but negative EBIT and net margins near -12%. The latest quarter showed $151.0M in revenue and a net loss of about $17.9M, or -$0.14 per share. Return metrics are all negative, and valuation is rich, with price-to-sales around 19x and price-to-cash-flow over 170x. This is a pure growth and execution story, not a value play.

Balance sheet strength is a key offset. 10x Genomics Inc. holds roughly $502.5M in cash and minimal debt, with a current ratio near 5.7, giving management room to invest in Atera and Perturb-seq. Operating cash flow last quarter was positive at about $17.0M, with free cash flow near $15.4M, helped by stock-based compensation and working-capital shifts. On the tape, intraday action shows a steady uptrend from the low $90s to mid-$94s before a modest fade into the close, suggesting active dip-buying and momentum participation.

Conclusion

The Atera rollout and analyst upgrades have flipped TXG into a momentum name that traders cannot ignore. Commercial shipments of Atera, aimed at high-resolution spatial biology and AI-driven drug discovery, are now live and reportedly above current manufacturing capacity. That narrative underpins Argus’s aggressive $110 target, while Piper Sandler, Leerink, and Deutsche Bank have all raised their numbers, even if some keep Neutral or Hold ratings. At the same time, 10x Genomics Inc. still carries steep losses and premium multiples, so the bar for future quarters is rising fast.

Recent price action in TXG — rallies to the low-to-mid $90s on heavy volume — reflects this tug-of-war between excitement and execution risk. For traders, the key is to treat it as a catalyst-driven growth trade. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” Applied here, that means respecting the volatility and taking disciplined trades around clear catalysts instead of swinging for home runs on every move. Watch how Atera adoption trends, any commentary on capacity expansion, and whether Perturb-seq demand shows up in revenue acceleration and margin improvement. Also respect that a hot run-up can mean sharp pullbacks if news flow cools.

As I teach my students, “The edge in a name like 10x Genomics comes from trading the reaction to real milestones, not from blindly chasing the story — you let the tape confirm that the fundamentals are actually showing up in the numbers.” This perspective helps keep TXG in the right bucket: a high-potential, high-volatility vehicle for disciplined, research-driven trading.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”